|

Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)

RECRUITINGSponsored by Istituto Nazionale di Ricovero e Cura per Anziani
Actively Recruiting
SponsorIstituto Nazionale di Ricovero e Cura per Anziani
Started2024-04-18
Est. completion2028-12-31
Eligibility
Age50 Years+
View on ClinicalTrials.gov →

NCT06902857

Summary

The Diabetes-CV study is an observational study designed to assess the prognostic value of serum cardiac damage markers high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP), and soluble suppression of tumorigenesis-2 (sST2) in predicting mortality, major adverse cardiovascular events, and diabetic complications in patients with type 2 diabetes.

Eligibility

Age: 50 Years+
Inclusion Criteria:

* type 2 diabetes
* patients attending the outpatient services

Exclusion Criteria:

* type 1 diabetes
* patients with active cancer or cancer in remission for less than 5 years
* any medical or other reason that leads the investigator to consider the subject ineligible for the study.

Conditions4

Cardiovascular ComplicationDiabetesHeart DiseaseType 2 Diabetes

Browse More Trials

Heart Disease trialsDiabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.